{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:40:47Z","timestamp":1777869647718,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.transproceed.2017.12.025","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T00:36:39Z","timestamp":1517618199000},"page":"124-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive\/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir"],"prefix":"10.1016","volume":"50","author":[{"given":"K.","family":"Nanmoku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Shinzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Yagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2017.12.025_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.ajkd.2011.04.010","article-title":"Human cytomegalovirus and kidney transplantation: a clinician's update","volume":"58","author":"De Keyzer","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transproceed.2017.12.025_bib2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/10898540-000000000-00000","article-title":"New developments in the management of cytomegalovirus infection after solid organ transplantation","volume":"70","author":"Eid","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.transproceed.2017.12.025_bib3","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/TP.0000000000000570","article-title":"Evaluation of low- versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients","volume":"99","author":"Gabardi","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.025_bib4","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/528718","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","volume":"46","author":"Arthurs","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2017.12.025_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/tid.12226","article-title":"Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+\/R-): experience from the RESITRA-REIPI cohort","volume":"16","author":"Meije","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2017.12.025_bib6","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/j.1600-6143.2010.03225.x","article-title":"Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis","volume":"10","author":"Helanter\u00e4","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.025_bib7","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1600-6143.2011.03611.x","article-title":"Impact of cytomegalovirus disease in D+\/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis","volume":"11","author":"Luan","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.025_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transproceed.2017.12.025_bib9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1128\/jcm.30.5.1232-1237.1992","article-title":"Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia","volume":"30","author":"Gerna","year":"1992","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.transproceed.2017.12.025_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2017.12.025_bib11","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/ajhp\/60.suppl_8.S13","article-title":"New prophylactic treatment strategy for cytomegalovirus disease","volume":"60","author":"Lake","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.transproceed.2017.12.025_bib12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2017.12.025_bib13","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1600-6143.2005.00797.x","article-title":"Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+\/R- transplant recipients","volume":"5","author":"Humar","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.025_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/rmv.513","article-title":"Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy","volume":"16","author":"Singh","year":"2006","journal-title":"Rev Med Virol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T11:15:22Z","timestamp":1635506122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134517308825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0041134517308825"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.12.025","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive\/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}